Literature DB >> 3491712

Interleukin 1 inhibitor masks high interleukin 1 production in acquired immunodeficiency syndrome (AIDS).

M A Berman, C I Sandborg, B S Calabia, B S Andrews, G J Friou.   

Abstract

Monocyte functions, including interleukin 1 (IL-1) production, have been shown previously to be impaired in acquired immunodeficiency syndrome (AIDS). We have fractionated culture supernatants from unstimulated peripheral blood mononuclear cells (PBMCs) to determine whether the low IL-1 activity in AIDS was due to the presence of IL-1 inhibitors. The results demonstrate that PBMCs from patients with AIDS produce increased amounts of IL-1 activity compared with those of controls together with marked increases (10- to 20-fold) in the amounts of 50,000-100,000 and 6000-9000 molecular weight (MW) factors which inhibit IL-1 activity. These inhibitors mask IL-1 activity measured in the standard thymocyte proliferation assay for IL-1. The 6000-9000 MW IL-1 inhibitor shows the greatest increase in all AIDS patients (n = 5) compared with that of controls (n = 7). This inhibitor may block the IL-1 dependent maturation of T lymphocytes in AIDS and thereby contribute to the immunodeficiency.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3491712     DOI: 10.1016/0090-1229(87)90180-2

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  19 in total

Review 1.  The respiratory syncitial virus and its role in acute bronchiolitis.

Authors:  M L Everard; A D Milner
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

2.  Impairment in T-lymphocyte responses during early infection with the human immunodeficiency virus.

Authors:  J Bentin; C D Tsoukas; J A McCutchan; S A Spector; D D Richman; J H Vaughan
Journal:  J Clin Immunol       Date:  1989-03       Impact factor: 8.317

3.  Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus.

Authors:  J M Molina; D T Scadden; R Byrn; C A Dinarello; J E Groopman
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

4.  Augmentation of lymphocyte and macrophage proliferation by caprine arthritis-encephalitis virus contributes to the development of progressive arthritis.

Authors:  K L Banks; M A Jutila; C A Jacobs; F H Michaels
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

5.  Release of interleukin 1 inhibitory activity (contra-IL-1) by human monocyte-derived macrophages infected with human immunodeficiency virus in vitro and in vivo.

Authors:  R M Locksley; S Crowe; M D Sadick; F P Heinzel; K D Gardner; M S McGrath; J Mills
Journal:  J Clin Invest       Date:  1988-12       Impact factor: 14.808

6.  Production of an interleukin-1 inhibitor by cell line P388D1 murine macrophages stimulated with Haemophilus actinomycetemcomitans lipopolysaccharide.

Authors:  T Nishihara; T Koga; S Hamada
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

7.  Expression of interleukin 2 receptors by monocytes from patients with acquired immunodeficiency syndrome and induction of monocyte interleukin 2 receptors by human immunodeficiency virus in vitro.

Authors:  J B Allen; N McCartney-Francis; P D Smith; G Simon; S Gartner; L M Wahl; M Popovic; S M Wahl
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

8.  Human immunodeficiency virus does not induce interleukin-1, interleukin-6, or tumor necrosis factor in mononuclear cells.

Authors:  J M Molina; D T Scadden; C Amirault; A Woon; E Vannier; C A Dinarello; J E Groopman
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

9.  Immunohistochemical demonstration of interleukin-1 receptor antagonist protein and interleukin-1 in human lymphoid tissue and granulomas.

Authors:  S W Chensue; K S Warmington; A E Berger; D E Tracey
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

10.  Human immunodeficiency virus-infected adherent cell-derived inhibitory factor (p29) inhibits normal T cell proliferation through decreased expression of high affinity interleukin-2 receptors and production of interleukin-2.

Authors:  A Ammar; Y Sahraoui; A Tsapis; A M Bertoli; C Jasmin; V Georgoulias
Journal:  J Clin Invest       Date:  1992-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.